Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Sobro in connection with the investment in NSS Group
Mandate

Vinge advises Sobro in connection with the investment in NSS Group

January 12, 2023 Real Estate and Construction M&A IT, Telecommunications and Outsourcing Banking and Finance Employment and Benefits Commercial Agreements Data protection and processing of personal data

Vinge advises Sobro in connection with the investment in NSS Group, a leading Nordic supplier of shelter solutions such as halls and tarpaulins.

NSS Group consists of Hallbyggarna Jonsereds (Sweden), Lainapeite (Finland) and IPS Hal & Presenning (Denmark). The group has a turnover of approximately SEK 300m and has 35 employees. NSS Group, with its roots in the 1950s, offers a modern and flexible range of products designed for the harsh Nordic climate and an international concept for logistics and procurement. Its customers are mainly found in the industrial and construction sectors.

Vinge’s team consisted of Johan Winnerblad, Elsie Nassar, Ellinor Wargenbrant and August Ahlin (M&A), Christoffer Nordin and Axel Lennartsson (Commercial Agreements), Karl-Gustaw Tobola (Banking and Financing), Kristoffer Larson (Real Estate and Environmental), Sara Passandideh (Employment), Nicklas Thorgerzon (IT and GDPR), Ian Jonsson (Intellectual Property) and Emelie Schoning (Project and VDR Assistant).

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024